IP Library Granted Patent US 7,232,572
Granted Patent B2
US 7,232,572 · App. 11/061,866 · Granted Jun 19, 2007

Methods of treating rosacea

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,232,572
App. No.
11/061,866
Granted
Jun 19, 2007
Kind
B2
Abstract

A method of treating rosacea in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat rosacea, but has substantially no antibiotic activity.

Claims (26)

1. A method for treating papules and pustules of rosacea in a human in need thereof comprising administering orally to said human a tetracycline compound, or a pharmaceutically acceptable salt thereof, in an amount that is effective to treat the papules and pustules of rosacea, but has substantially no antibiotic activity, said amount being 10-80% of the antibiotic amount, wherein the tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount that results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

2. A method according to claim 1 , wherein said tetracycline compound is minocycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of 0.8 μg/ml.

3. A method according to claim 1 , wherein said tetracycline compound is tetracycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of 0.5 μg/ml.

4. A method according to claim 1 , wherein said tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration which is 10-80% of the minimum antibiotic serum concentration.

5. A method according to claim 4 , wherein said antibiotic tetracycline compound is doxycycline, minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound.

6. A method according to claim 5 , wherein said antibiotic tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof.

7. A method according to claim 6 , wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μg/ml.

8. A method according to claim 6 , wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 20 milligrams twice daily.

9. A method according to claim 7 , wherein said doxycycline or pharmaceutically acceptable salt thereof is administered by sustained release.

10. A method according to claim 9 , wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 40 milligrams.

11. A method according to claim 1 , wherein said tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount which is 10-70% of the antibiotic amount.

12. A method according to claim 1 , wherein said tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof.

13. A method according to claim 12 , wherein said doxycycline is doxycycline monohydrate.

14. A method according to claim 12 , wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 40 milligrams.

15. A method according to claim 14 , wherein said doxycycline or pharmaceutically acceptable salt thereof is administered by sustained release.

16. A method according to claim 12 , wherein said doxycycline or pharmaceutically acceptable salt thereof is administered twice a day in a dose of 20 mg.

17. A method according to claim 1 , wherein said tetracycline compound is minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound.

18. A method according to claim 4 , wherein said tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of approximately 1.0 μg/ml.

19. A method according to claim 4 , wherein said tetracycline compound is minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound.

20. A method for treating papules and pustules of rosacea in a human in need thereof comprising administering orally to said human a hydrate of doxycycline in an amount that is effective to treat the papules and pustules of rosacea, but has substantially no antibiotic activity, said amount being 10-80% of the antibiotic amount, wherein the hydrate of doxycycline is administered in an amount that results in no reduction of skin microflora during a six-month treatment, said method not comprising administering a bisphosphonate compound.

21. A method according to claim 20 , wherein said hydrate of doxycycline is doxycycline monohydrate.

22. A method according to claim 20 wherein said hydrate of doxycycline is administered in an amount which is 10-70% of the antibiotic amount.

23. A method according to claim 20 , wherein said hydrate of doxycycline is administered in an amount of 40 milligrams.

24. A method according to claim 20 , wherein said hydrate of doxycycline is administered by sustained release.

25. A method according to claim 20 , wherein said hydrate of doxycycline is administered twice a day in a dose of 20 mg.

26. A method according to claim 23 , wherein said hydrate of doxycycline is administered once a day.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2011
From: COLLAGENEX PHARMACEUTICALS, INC.
To: GALDERMA LABORATORIES INC.
Reel/Frame 027369/0215 →